Triple-Negative Breast Cancer: Current Understanding and Future Therapeutic Breakthrough Targeting Cancer Stemness
Year: 2019
Type: review
Abstract: Triple-negative breast cancer (TNBC) is cancer that tested as negative for estrogen receptors (ER), progesterone receptors (PR), and excess human epidermal growth factor receptor 2 (HER2) protein which accounts for 15%-20% of all breast cancer cases. TNBC is considered to be a poorer prognosis than other types of breast cancer, mainly because it involves more aggressive phenotypes that are similar to stem cell-like cancer cells (cancer stem cell, CSC). Thus, targeted treatment of TNBC remains a major challenge in clinical practice. This review article surveys the latest evidence concerning the role of genomic alteration in current TNBC treatment responses, current clinical trials and potential targeting sites, CSC and drug resistance, and potential strategies targeting CSCs in TNBC. Furthermore, the role of insulin-like growth factor 1 receptor (IGF-1R) and nicotinic acetylcholine receptors (nAChR) in stemness expression, chemoresistance, and metastasis in TNBC and their relevance to potential treatments are also discussed and highlighted.
Source: Cancers
Institutions: Taipei Medical University, Taipei Medical University Hospital
Language: English
Subfield: Cancer Research
Domain: Life Sciences
Open Access status: gold
Estimated APC paid: $1,824
Awards: G1052468712, G1376316170, G1466199474, G2645814517, Role of Niche Inflammatory Cytokine and Epigenetic Regulation in Expressions of Pluripotent Transcription Factor Oct4 and Sorafenib Refractoriness in Hbv-Related Hepatocellular Carcinoma and Its Clinical Implication.(I), G3883000693, G4085703641, G4119808879, G4398850191, G4556133915, G4643447831, Systemic Safety Allograft Strategies for Cell Therapeutic Product Development: Targeting Unmet Medical Need Human Chronic Inflammatory Disease - Diabetes Mellitus /Decubitus Wound, Severe Burn, and Multiple Sclerosis( I ), G497937365, Studies on the Mechanisms of Histamine N-Methyl-Transferase (Hnmt) as a Novel Molecular Marker to Help Clinician for Identifying of Herceptin Responder in Breast Cancer Patients, G534818986, G5571782644, G5630210192, G6189269271, G6592722272, G6600516246, Systemic Safety Allograft Strategies for Cell Therapeutic Product Development: Targeting Unmet Medical Need Human Chronic Inflammatory Disease - Diabetes Mellitus /Decubitus Wound, Severe Burn, and Multiple Sclerosis( III ), Systemic Safety Allograft Strategies for Cell Therapeutic Product Development: Targeting Unmet Medical Need Human Chronic Inflammatory Disease - Diabetes Mellitus /Decubitus Wound, Severe Burn, and Multiple Sclerosis( II ), G737106015, G7379527416, G7693006461, G7743120553, G8071098059, G939887807
OpenAlex ID: W2972270957
